CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Somatic mutations in salivary duct carcinoma and potential therapeutic targets
Authors
Michael J. Boyer
Jonathan R. Clark
+13 more
Angus J. Clarke
Mark J. Cowley
Marcel E. Dinger
Ruta Gupta
Timothy K. Khoo
Spiridoula Kraitsek
Peter P. Luk
Kate L. Mahon
Sandra A. (R17255) O'Toole
Carsten Palme
Christina I. Selinger
Joel A. Smith
Bing Yu
Publication date
1 January 2017
Publisher
'Impact Journals, LLC'
Doi
Cite
Abstract
Background: Salivary duct carcinomas (SDCa) are rare highly aggressive malignancies. Most patients die from distant metastatic disease within three years of diagnosis. There are limited therapeutic options for disseminated disease. Results: 11 cases showed androgen receptor expression and 6 cases showed HER2 amplification. 6 Somatic mutations with additional available targeted therapies were identified: EGFR (p. G721A: Gefitinib), PDGFRA (p. H845Y: Imatinib and Crenolanib), PIK3CA (p. H1047R: Everolimus), ERBB2 (p. V842I: Lapatinib), HRAS (p. Q61R: Selumetinib) and KIT (p. T670I: Sorafenib). Furthermore, alterations in PTEN, PIK3CA and HRAS that alter response to androgen deprivation therapy and HER2 inhibition were also seen. Materials and Methods: Somatic mutation analysis was performed on DNA extracted from 15 archival cases of SDCa using the targeted Illumina TruSeq Amplicon Cancer Panel. Potential targetable genetic alterations were identified using extensive literature and international somatic mutation database (COSMIC, KEGG) search. Immunohistochemistry for androgen receptor and immunohistochemistry and fluorescent in situ hybridization for HER2 were also performed. Conclusions: SDCa show multiple somatic mutations, some that are amenable to pharmacologic manipulation and others that confer resistance to treatments currently under investigation. These findings emphasize the need to develop testing and treatment strategies for SDCa. © Khoo et al
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Western Sydney ResearchDirect
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:researchdirect.westernsydn...
Last time updated on 12/07/2022